๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

JY231

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our China register that name JY231 as an intervention. Synced 24 Sep 2026
7Trials tracked
5Recruiting now
5Lead sponsors
1Country register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

JY231 is named as a drug or biological intervention in 7 clinical trials in our China trial register, 5 of which are recruiting. Lead sponsors include 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2), He Huang (2) and Shenzhen Genocury Biotech Co., Ltd. (1). Registered phases: Not applicable and Phase EARLY_PHASE1. Conditions studied include B-ALL; B-Non Hodgkin Lymphoma; B-NHL.

01

Clinical trials of JY231

7 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06514768 JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) (ClinicalTrials.gov ↗)
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase EARLY_PHASE1 Recruiting 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China China
NCT06678282 JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia (ClinicalTrials.gov ↗)
B-NHL, B-ALL
Not applicable Recruiting Shenzhen Genocury Biotech Co., Ltd. China
NCT06940960 JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia (ClinicalTrials.gov ↗)
B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
Not applicable Recruiting Affiliated Hospital of Guangdong Medical University China
NCT07059169 CAR-T Therapy for Refractory Autoimmune Diseases (ClinicalTrials.gov ↗)
Autoimmune Diseases
Not applicable Recruiting LiangZou China
NCT07065279 JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies (ClinicalTrials.gov ↗)
B-cell Malignancies
Not applicable Recruiting 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China China
NCT06879470 JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma (ClinicalTrials.gov ↗)
B-Non Hodgkin Lymphoma
Not applicable Not yet open He Huang China
NCT06902025 JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia (ClinicalTrials.gov ↗)
B-ALL
Not applicable Not yet open He Huang China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

7 conditions
Condition (as registered)Trials
B-ALL2
B-Non Hodgkin Lymphoma2
B-NHL1
B-cell Acute Lymphoblastic Leukemia (B-ALL)1
Autoimmune Diseases1
B Acute Lymphoblastic Leukemia1
B-cell Malignancies1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China2
He Huang2
Shenzhen Genocury Biotech Co., Ltd.1
LiangZou1
Affiliated Hospital of Guangdong Medical University1
04

Trials by country register

RegisterJY231 trials
Clinical trials in China7

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how JY231 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JY231 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.